NICE recommends Axicabtagene ciloleucel for DLBCL
Published on: 1 February 2023New treatment available for relapsed or refractory diffuse large B-cell lymphoma or primary mediastinal large B-cell lymphoma
The National Institute for Health and Care Excellence (NICE) has recommended Axicabtagene ciloleucel as an option for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or primary mediastinal large B-cell lymphoma in adults after 2 or more systemic (whole body) therapies.
Axicabtagene ciloleucel is a type of treatment known as ‘CAR T-cell therapy’. This treatment uses your own immune system to try to destroy lymphoma cells. Your body produces a type of lymphocyte (white blood cell), called a T cell, to fight infections and diseases, including lymphoma. Axicabtagene ciloleucel is made from your own T cells.
New data and evidence collected as part of the Cancer Drugs Fund shows that people having axicabtagene ciloleucel live longer than people having salvage chemotherapy and have longer before their condition gets worse.
Find out more about drug development, approval and funding, or visit Lymphoma TrialsLink for the latest on clinical trials for lymphoma.
Published: 1st February 2023